Pain & Migraine Peptides

Pain-related peptides include both endogenous neuropeptides that mediate nociceptive signaling and therapeutic agents developed to interrupt pain pathways. This category has seen some of the most significant pharmaceutical advances in recent years, particularly in the field of migraine prevention.

Ziconotide, derived from cone snail venom, is the only FDA-approved N-type calcium channel blocker, administered intrathecally for severe chronic pain refractory to other treatments. Substance P and CGRP (calcitonin gene-related peptide) are endogenous neuropeptides with well-established roles in pain transmission and migraine pathophysiology. The discovery that CGRP is a key mediator of migraine attacks led to the development of monoclonal antibodies targeting the CGRP pathway: erenumab (targeting the CGRP receptor), fremanezumab (targeting the CGRP ligand), and galcanezumab (also targeting the CGRP ligand). These antibodies, all FDA-approved since 2018, represent a paradigm shift in migraine prevention.

The evidence base for pain peptides is generally strong. The CGRP-targeting antibodies have been evaluated in large Phase 3 trials enrolling thousands of patients, while ziconotide's efficacy was demonstrated in multiple randomized controlled trials for intractable chronic pain.